Keryx Biopharmaceuticals Inc (KERX) financial statements (2022 and earlier)

Company profile

Business Address ONE MARINA PARK DR.
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments93,526111,810200,29085,79255,69614,677
Cash and cash equivalents93,526111,810200,29074,28455,69614,677
Short-term investments   11,508  
Receivables8,1465,2364,293882  
Inventory, net of allowances, customer advances and progress billings28,69512,68141,8817,830
Inventory28,69512,68141,8817,830  
Prepaid expense and other current assets430
Other current assets11,1993,1702,8304,0921,232
Total current assets:141,566132,897249,29498,59656,92815,107
Noncurrent Assets
Property, plant and equipment4,5214,2115,0831,53234956
Intangible assets, net (including goodwill)3,2083,2083,2082,8562,8562,856
Goodwill3,2083,2083,2083,2083,2083,208
Intangible assets, net (excluding goodwill)   (352)(352)(352)
Other noncurrent assets9,5771,1111,100292281
Prepaid expense and other noncurrent assets198
Other undisclosed noncurrent assets   352352352
Total noncurrent assets:17,3068,5309,3915,0323,8383,462
TOTAL ASSETS:158,872141,427258,685103,62860,76618,569
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:45,03121,19021,32224,14614,0047,212
Accounts payable6,4742,225    
Accrued liabilities21,86310,775244   
Employee-related liabilities7,5048,1905,4734,7511,324827
Other undisclosed accounts payable and accrued liabilities9,190 15,60519,39512,6806,385
Derivative instruments and hedges, liabilities  46,686   
Deferred revenue and credits  3,526414  
Other liabilities145117355   
Other undisclosed current liabilities2442445,7174,7511,324827
Total current liabilities:45,42021,55177,60629,31115,3288,039
Noncurrent Liabilities
Long-term debt and lease obligation125,000125,00090,773   
Long-term debt, excluding current maturities125,000125,00090,773   
Liabilities, other than long-term debt1,9122,3023,3728333836
Deferred revenue and credits1,0181,2621,506   
Deferred tax liabilities, net  790700  
Other liabilities8941,0401,0761333836
Other undisclosed noncurrent liabilities635870    
Total noncurrent liabilities:127,547128,17294,1458333836
Total liabilities:172,967149,723171,75130,14415,3668,075
Stockholders' equity
Stockholders' equity attributable to parent(14,095)(8,296)86,93473,48445,40010,494
Common stock119106105938372
Treasury stock, value(357)(357)(357)(357)(357)(357)
Additional paid in capital984,681827,053761,189624,606485,014403,387
Accumulated deficit(998,538)(835,098)(674,003)(550,858)(439,340)(392,608)
Total stockholders' equity:(14,095)(8,296)86,93473,48445,40010,494
TOTAL LIABILITIES AND EQUITY:158,872141,427258,685103,62860,76618,569

Income statement (P&L) ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues60,64131,98313,68011,7257,000166
Revenue, net60,64131,98313,68011,7257,161166
Cost of revenue
(Cost of Goods and Services Sold)
(3,467)(27,968)(2,600)(495)  
Gross profit:57,1744,01511,08011,2307,000166
Operating expenses(162,332)(154,746)(124,748)(122,054)(54,083)(27,079)
Other undisclosed operating income (loss)3,46727,9682,600(405) (166)
Operating loss:(101,691)(122,763)(111,068)(111,229)(47,083)(27,079)
Nonoperating income (expense)(61,984)(38,252)(11,987)4113511,719
Other nonoperating income (expense)981(4,025)(11,987)4113511,719
Interest and debt expense(63,000)(34,209)(11,357)   
Other undisclosed income from continuing operations before equity method investments, income taxes63,00034,20911,357   
Loss from continuing operations before income taxes:(163,675)(161,015)(123,055)(110,818)(46,732)(25,360)
Income tax expense (benefit)235(80)(90)(700) 15,190
Net loss:(163,440)(161,095)(123,145)(111,518)(46,732)(10,170)
Other undisclosed net loss attributable to parent     (12,551)
Net loss available to common stockholders, diluted:(163,440)(161,095)(123,145)(111,518)(46,732)(22,721)

Comprehensive Income ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(163,440)(161,095)(123,145)(111,518)(46,732)(10,170)
Comprehensive loss:(163,440)(161,095)(123,145)(111,518)(46,732)(10,170)
Other undisclosed comprehensive loss, net of tax, attributable to parent     (12,551)
Comprehensive loss, net of tax, attributable to parent:(163,440)(161,095)(123,145)(111,518)(46,732)(22,721)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: